Blue Owl
VC Fund
New York, United States
Blue Owl is a VC fund in New York focused on Biotechnology and Health Care. Blue Owl Capital is an alternative asset manager that provides investors access to direct lending and GP capital solutions strategies through a variety of vehicles. The firm's breadth of offerings and permanent capital base enables it to offer a differentiated, holistic platform of capital solutions to participants throughout the privatemarket ecosystem, including alternative asset managers and private middle market corporations.
- Total investments:
- 83
- Last investment:
- Lead investor:
- 49%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Blue Owl invests in
Stages Blue Owl invests in
Countries Blue Owl invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 31 (37%)
- Health Care 21 (25%)
- Therapeutics 13 (16%)
- Pharmaceutical 12 (14%)
- Life Science 10 (12%)
Stage
- Debt Financing 21 (25%)
- Post-IPO Equity 16 (19%)
- Series B 6 (7%)
- Post-IPO Debt 6 (7%)
- Private Equity 6 (7%)
Country
- United States 54 (65%)
- United Kingdom 8 (10%)
- Canada 5 (6%)
- Switzerland 2 (2%)
- China 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Darragh O’Flaherty
Principal
|
Principal | Total investments: 2 | Find email | |
|
Kevin Raidy
Senior Managing Director
|
Senior Managing Director | Total investments: 1 | Find email | |
Marc Lipschultz
Co-CEO
|
Co-CEO | Total investments: 0 | Find email | |
Alan Kirshenbaum
CFO
|
CFO | Total investments: 0 | Find email | |
Alicia Gregory
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
| See all 17 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
BlackFin Capital Partners
|
BlackFin is a sector-focused fund, specializing in Financial Services in Europe.The firm’s strategy focuses on asset-light (as opposed to balance-sheet intensive) businesses in the financial services sector, across continental Europe. BlackFin operates as an active and influential investor, substantially transforming its portfolio companies bygrowing them organically, improving operating margins and also through an active buy and build strategy. The firm supports successful management teams to take their businesses to the next level. | Private Equity / Jul 15, 2026 | |
|
Affinius Capital and Corscale Data Centers JV
|
Affinius Capital and Corscale Data Centers is a joint venture firm | $975M / Debt Financing / Jun 08, 2026 | |
Perk (formerly TravelPerk)
|
TravelPerk is a next-generation business travel booking and management platform for companies of any size. It is an all-in-one platform for booking business travel. TravelPerk is backed by investors such as Spark Capital, investors in Slack, Trello, and Twitter. The company is co-founded and funded by a team of entrepreneurial executives with deepmarket expertise, including leadership-level experience, as one of the successful players in the online travel industry. One of the co-founders recently started and sold a travel technology company to one of the players in the market.TravelPerk was founded in 2015 and is headquartered in Barcelona, Catalonia. | $300M / Debt Financing / Jun 03, 2026 | |
Artiva Biotherapeutics
|
Artiva Biotherapeutics is a private biotech company advancing a pipeline of off-the-shelf, allogeneic NK cell therapies, for the treatment of hematologic cancers or solid tumors. It was founded on the understanding that NK cells hold enormous therapeutic potential as cancer therapies and the dedication and expertise to overcome technologicalbarriers in the scaling and manufacturing of these cells. At Artiva, its mission is to deliver highly effective cell therapies that are also safe and immediately available and accessible to any cancer patient who stands to benefit. Artiva’s platform delivers scalability, quality, and cryopreservation to support a pipeline of safe, effective, versatile, and accessible product candidates. | $300M / Post-IPO Equity / May 08, 2026 | |
Sagimet Biosciences
|
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASNinhibitors. | $175M / Post-IPO Equity / Apr 27, 2026 | |
Ambrosia Biosciences
|
Ambrosia Biosciences offers drug development services for small molecule-based therapies for obesity and other metabolic disorders. | $100M / Series B / Mar 31, 2026 | |
Atlas Holdings
|
Atlas Holdings is a diversified group of manufacturing, distribution, service and trading businesses that operates in the building materials, capital equipment, energy, industrial services, packaging, pulp, paper, and tissue, steel, and logistics, supply chain management and distribution segments. With a unique and focused approach, Atlas Holdingshas built companies and entered new industries, centered around investing in businesses undergoing complex financial and operational challenges, developing exceptional management teams joined by a shared set of values and common culture, and deploying the Atlas operating system. | Private Equity / Mar 10, 2026 | |
Nexthink
|
Nexthink is a global leader in digital experience management. The company's product allows enterprises to create highly productive digital workplaces for their employees by delivering optimal end-user experience. Through a unique combination of real-time analytics, automation and employee feedback across all endpoints, Nexthink helps ITteams meet the needs of the modern digital workplace. | $750M / Debt Financing / Mar 06, 2026 | |
Scholar Rock
|
Scholar Rock, Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our newly elucidated understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietaryplatform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. We believe this approach, acting in the disease microenvironment, avoids the historical challenges associated with inhibiting growth factors for therapeutic effect. We believe our focus on biologically validated growth factors may facilitate a more efficient development path. We are advancing our lead product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, into clinical development for the treatment of spinal muscular atrophy, or SMA. We expect to initiate a Phase 1 clinical trial in the second quarter of 2018. Utilizing our proprietary platform, we are also creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including other neuromuscular disorders, cancer, fibrosis and anemia. | $100M / Post-IPO Debt / Mar 03, 2026 | |
Allica Bank
|
Allica Bank provides business banking services focused on supporting established small and medium-sized enterprises through lending, savings, and current account products. Its offering includes commercial mortgages, asset finance, and bridging loans designed to support property investment and operational funding needs. The bank also deliversbusiness current accounts with payment capabilities and tools that help companies manage cash flow. In addition, it provides savings accounts for both businesses and personal customers seeking interest-bearing deposit options. Its services are delivered through a combination of digital tools and relationship-based support to assist financial management and funding access. | $155M / Series D / Feb 25, 2026 | |
| See all 83 investments → | |||
Co-Investors
Deep Track Capital
11 deals together
Biotechnology Value Fund
8 deals together
Blackstone
8 deals together
RTW Investments
8 deals together
Foresite Capital
7 deals together
OrbiMed
7 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Blue Owl invest in?
Blue Owl invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Debt Financing and Post-IPO Equity stage. Most of the 83 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Blue Owl?
Public channels for Blue Owl include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Blue Owl?
The team at Blue Owl includes Darragh O’Flaherty (Principal), Kevin Raidy (Senior Managing Director) and Marc Lipschultz (Co-CEO), among 17 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
